Searched for
GLAND PHARMA PROFIT
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Nifty IT bottoming out? Anand James on the expiry outlook, pharma profit-booking, and 2 stocks to buy this weekGeojit Investments’ Anand James expects Nifty to attempt a range breakout above 23,700 during the monthly expiry week. He highlighted early...
- F&O Talk: Weak market breadth to keep Nifty in sideways trend. Sudeep Shah's take on Amber, Tata Comm and 4 more stocksIndian markets ended higher on Friday, led by financial stocks, but analysts said Nifty remains trapped in a narrow range amid weak momentu...
- Cenexi recovery, new product launches and capacity additions power Gland Pharma outlookGland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving p...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Ahead of Market: 10 things that will decide stock market action on WednesdayDomestic equities closed marginally lower due to weakness in financial and consumer shares, despite gains in IT stocks. Analysts suggest th...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividendShares of Gland Pharma rallied on Monday after the company reported a 97% YoY surge in Q4 profit and strong revenue growth, driven by its C...
- Gland Pharma Q2 Results: Profit rises 12% to Rs 184 croreGland Pharma on Monday reported 12 per cent year-on-year increase in profit after tax (PAT) at Rs 184 crore for the September quarter, aide...
- Gland Pharma Q4 Results: Net profit down 3% at Rs 186 croreGland Pharma Ltd on Tuesday reported a 3 per cent decline in consolidated net profit to Rs 186.54 crore in the fourth quarter ended March 3...
- Gland Pharma shares fall over 4% after weak Q3 result, Jefferies target price cutGland Pharma share price: Revenue from operations fell 10% year-on-year to Rs 1,384 crore. EBITDA increased by 1% year-on-year to Rs 360 cr...
- Gland Pharma Q3 net profit rises 7% to Rs 205 croreGland Pharma on Monday reported 7% year-on-year (YoY) rise in net profit to Rs 205 crores in Q3FY25.
- Gland Pharma shares zoom 12% post Q2 results; Kotak upgrades on limited downsideGland Pharma Share Price: Gland Pharma shares rose 12% despite a 15.7% YoY profit decline in Q2. Kotak upgraded the stock to 'Reduce' with ...
- Gland Pharma shares hit 20% lower circuit after disappointing Q4 resultsGland Pharma's stock prices hit a 20% lower circuit on BSE after the firm reported a 72% YoY drop in net profit to Rs 79 crore in Q4FY23 du...
- Gland says not heard from its promoter Fosun about the potential saleThe debt-laden Chinese conglomerate Fosun controlled by billionaire entrepreneur Guo Guangchang has been looking to sell non-core assets, t...
- Gland Pharma slides further on weak Q2, stress at FosunThe pessimistic outlook by the rating agency triggered speculation that the Chinese firm may likely sell its stake in the Indian pharma com...
- 6 must-reads of ET Wealth: 6 stocks with up to 41% upside potential, why Gland Pharma is this week's stock pickA rundown of the six most important stories from Wealth this week. We tell you why analysts are bullish on Gland Pharma, 6 stocks with stro...
- Gland Pharma shares rally nearly 8%; at 52-week high after Q1 earningsDrug firm Gland Pharma on Wednesday reported an 11.83 per cent increase in its consolidated net profit to Rs 350.7 crore for the quarter en...
- Gland Pharma Q1 results: Net profit rises 12% to Rs 351 crConsolidated revenue from operations of the company stood at Rs 1,153.9 crore for the quarter under consideration. It was Rs 884.2 crore fo...
- Buy Gland Pharma, target price Rs 2700: Motilal OswalGland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 37108.47 Crore) operating in Pharmaceut...
Load More
